Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 3, 2015, Pages 564-571

  You, Joyce H S ^a   Ming, Wai Kit ^a   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cost effectiveness analysis; Hong Kong; Influenza B; Quadrivalent influenza vaccine; Trivalent influenza vaccine; Victoria lineage; Yamagata lineage

Indexed keywords

INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BASE CASE ANALYSIS; CASE STUDY; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIRECT COST; DRUG COST; HEALTH CARE COST; HONG KONG; HUMAN; INCREMENTAL COST PER QUALITY ADJUSTED LIFE YEAR; INDIRECT COST; INFANT; INFECTION PREVENTION; INFLUENZA B; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MIDDLE AGED; MONTE CARLO METHOD; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SENSITIVITY ANALYSIS; VERY ELDERLY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; NEWBORN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HONG KONG; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 84928655513     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011016     Document Type: Article

References (31)

1. Chan PK, Chan MC, Cheung JL, Lee N, Leung TF, Yeung ACM, Wong MCS, Ngai KLK, Nelson AS, Hui DSC. Influenza B lineage circulation and hospitalization rates in a subtropical city, hong kong, 2000-2010. Clin Infect Dis 2013; 56:677-84; PMID:23074315; http://dx.doi.org/10.1093/cid/cis885.
2. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8; PMID:22226861; http://dx.doi.org/10.1016/j.vaccine.2011.12.098.
3. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2013; 31:2477-9; PMID:23084849; http://dx.doi.org/10.1016/j.vaccine.2012.10.025.
4. You JHS, Wong WCW, Ip M, Lee NLS, Ho SC. Costeffectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Commun Health 2009; 63:906- 11; PMID:19608558; http://dx.doi.org/10.1136/jech.2008.081885.
5. Census and Statistics Department, The government of hong kong SAR. Assessed on 24 October 2013: http://www.censtatd.gov.hk/.
6. Chan D. Seasonal influenza vaccination coverage survey for the 2012/2013 season. Commun Dis Watch 2013; 10:74-7.
7. Centers for Disease Control and Prevention. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-marshfield, wisconsin, 2007-08 influenza season. Morb Mortal Wkly Rep 2008; 57:393-8; PMID:18418344.
8. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http://dx.doi.org/10.1086/656578.
9. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7; PMID:19776407; http://dx.doi.org/10.1056/NEJMoa0808652.
10. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22; PMID:17167134; http://dx.doi.org/10.1056/NEJMoa061850.
11. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-7; PMID:18522501; http://dx.doi.org/10.1086/589885.
12. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric LiY, Sebastian R, Chong M, Tam T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842-51; PMID:17081662; http://dx.doi.org/10.1016/j.vaccine.2006.10.002.
13. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500-8; PMID:21220776; http://dx.doi.org/10.1093/infdis/jiq076.
14. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, et al. Effectiveness of seasonal influenza vaccines in the united states during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951-9; PMID:22843783; http://dx.doi.org/10.1093/cid/cis574.
15. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RYK, Lee ELY, Yeung ACM, Ngai KLK, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739-47; PMID:21606532; http://dx.doi.org/10.1093/infdis/jir187.
16. Kwong KL, Lung D, Wong SN, Que TL, Kwong NS. Influenza-related hospitalisations in children. J Paediatr Child Health 2009; 45:660-4; PMID:19845841; http://dx.doi.org/10.1111/j.1440-1754.2009.01591.x.
17. Chowell G, Miller MA, Viboud C. Seasonal influenza in the united states, france, and australia: Transmission and prospects for control. Epidemiol Infect 2008; 136:852-64; PMID:17634159.
18. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 2010; 201:167-10; PMID:20402594; http://dx.doi.org/10.1086/652404.
19. Cowling BJ, Chan KH, Feng S, Chan EL, Lo JY, Peiris JS, Chiu SS. The effectiveness of influenza vaccination in preventing hospitalizations in children in hong kong, 2009-2013. Vaccine 2014; 15;32:5278-84; PMID:25092636; http://dx.doi.org/10.1016/j.vaccine.2014.07.084.
20. Sander B, Hayden FG, Gyldmark M, Garrison LPJ. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 2006; 24:373-86; PMID:16605283; http://dx.doi.org/10.2165/00019053-200624040-00007.
21. Talbird SE, Brogan AJ, Winiarski AP, Sander B. Costeffectiveness of treating influenza-like illness with oseltamivir in the united states. Am J Health-Syst Pharm 2009; 66:469-480; PMID:19233995; http://dx.doi.org/10.2146/ajhp080296.
22. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effective analysis. Am J Med 2005; 118:68-77; PMID:15639212; http://dx.doi.org/10.1016/j.amjmed.2004.03.044.
23. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in australia. Pharmacoeconomics 2000; 17:11- 620; PMID:10977398; http://dx.doi.org/10.2165/00019053-200017060-00007.
24. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children ages 24-59 months in the united states. Vaccine 2008; 26:2841-8; PMID:18462851; http://dx.doi.org/10.1016/j.vaccine.2008.03.046.
25. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38:583-637; PMID:10843310; http://dx.doi.org/10.1097/00005650-200006000-00004.
26. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978; 31:697-704; PMID:730825; http://dx.doi.org/10.1016/0021-9681(78)90072-3.
27. Petrie JG, Ohmit SE, Hohnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011; 203:1309-15; PMID:21378375; http://dx.doi.org/10.1093/infdis/jir015.
28. Chiu SS, Chan KH, So LY, Chen R, Chan ELY, Peiris JSM. The population based socioeconomic burden of pediatric influenza-associated hospitalization in Hong Kong. Vaccine 2012; 30:1895-1900; PMID:22222872; http://dx.doi.org/10.1016/j.vaccine.2011.12.027.
29. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Medical Care 1998; 36:778-92; PMID:9630120; http://dx.doi.org/10.1097/00005650-199806000-00002.
30. Fees and Charges, Hospital Authority, Hong Kong. Assessed on 7 October 2013: http://www.ha.org.hk.
31. Cost-effectiveness thresholds. World health organization. Assessed on 3 December 2013: http://www.who.int/choice/costs/CER-thresholds/en/index.html.